Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

Osteoporosis International

Volumn 20, Issue 10, 2009, Pages 1663-1673

  Meunier, P J ^a,b   Roux, C ^c   Ortolani, S ^d   Diaz Curiel, M ^e   Compston, J ^f   Marquis, P ^g   Cormier, C ^h   Isaia, G ⁱ   Badurski, J ^j   Wark, J D ^k   Collette, J ^l   Reginster, J Y ^m  

^a UNIVERSITÉ LYON 1   (France)

^b Hôpital Cochin ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g MAPI VALUES   (United States)

^h Università Degli Studi Torino ^*  (France)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j Center of Osteoporosis and Osteo articular Diseases   (Poland)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l UNIVERSITY OF LIÈGE   (Belgium)

^m UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

Bone densitometry; Menopause; Osteoporosis treatment; Osteoporotic fracture; Strontium ranelate

Indexed keywords

STRONTIUM RANELATE;

ADULT; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; EMBOLISM; FEMALE; HEADACHE; HUMAN; LICHEN PLANUS; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PEMPHIGOID; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALIOST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SHORT FORM 36; SIDE EFFECT; VEIN THROMBOSIS; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; QUALITY OF LIFE; SPINAL FRACTURES; THIOPHENES; TREATMENT OUTCOME;

EID: 69949149543     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0825-6     Document Type: Article

References (45)

1. European Prospective Osteoporosis Study 2002 Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS) J Bone Miner Res 17 716 724
2. Cummings SR, Melton LJ, III 2002 Epidemiology and outcomes of osteoporotic fractures Lancet 359 1761 1767
3. CM Klotzbuecher PD Ross PB Landsman, et al. 2000 Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis J Bone Miner Res 15 721 739
4. JR Center TV Nguyen D Schneider, et al. 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 878 882
5. S Puffer DJ Torgerson D Sykes, et al. 2004 Health care costs of women with symptomatic vertebral fractures Bone 35 383 386 (Pubitemid 38953183)
6. M Schwenkglenks K Lippuner HJ Hauselmann, et al. 2005 A model of osteoporosis impact in Switzerland 2000-2020 Osteoporos Int 16 659 671
7. MC Nevitt B Ettinger DM Black, et al. 1998 The association of radiographically detected vertebral fractures with back pain and function: a prospective study Ann Intern Med 128 793 800
8. AM Oleksik S Ewing W Shen, et al. 2005 Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures Osteoporos Int 16 861 870
9. SK Brenneman E Barrett-Connor S Sajjan, et al. 2006 Impact of recent fracture on health-related quality of life in postmenopausal women J Bone Miner Res 212 809 816
10. J Fechtenbaum C Cropet S Kolta, et al. 2005 The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women Osteoporos Int 16 2175 2179
11. PJ Marie P Ammann G Boivin, et al. 2001 Mechanisms of action and therapeutic potential of strontium in bone Calcif Tissue Int 69 121 129
12. TC Brennan MS Rybchyn P Halbout, et al. 2007 Strontium ranelate effects in human osteoblasts support its uncoupling effect on bone formation and bone resorptions Bone Miner Res 22 Suppl.1 S139
13. PJ Meunier DO Slosman PD Delmas, et al. 2002 Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial J Clin Endocrinol Metab 87 2060 2066
14. PJ Meunier C Roux E Seeman, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis New Engl J Med 350 459 468 (Pubitemid 38133766)
15. JY Reginster E Seeman MC De Vernejoul, et al. 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 2822
16. JY Reginster D Felsenberg S Boonen, et al. 2008 Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial Arthritis and Rheumatism 58 6 1687 1695
17. DO Slosman R Rizzoli C Pichard, et al. 1994 Longitudinal measurement of regional and whole-body bone mass in young healthy adults Osteoporos Int 4 185 190
18. postmenopausal osteoporosis Osteoporos Int 14 Suppl 3 S66 S76
19. HK Genant CY Wu C van Kuijk, et al. 1993 Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 8 1137 1148
20. LJ Melton III M Thamer NF Ray, et al. 1997 Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation J Bone Miner Res 12 16 23
21. DO Slosman DM Provvedini PJ Meunier, et al. 1999 The use of different dual x-ray absorptiometry brands in a multicenter clinical trial J Clin Densitom 2 37 44
22. SP Nielsen D Slosman OH Sorensen, et al. 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry J Clin Densitom 2 371 379
23. Ware JE, Kosinski MK, Keller SD (1994) SF-36 physical and mental health summary scales: a users manual. The Health Institute, New England Medical Center, Boston, MA, USA
24. P Marquis P Cialdella C De la Loge 2001 Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST Qual Life Res 10 555 566
25. C De la Loge K Sullivan R Pinkney, et al. 2005 Cross-cultural validation and analysis of responsiveness of the QUALIOST: QUAlity of Life questionnaire In OSTeoporosis Health Qual Life Outcomes 3 69
26. SR Cummings DM Black DE Thompson, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082
27. PD Delmas KE Ensrud JD Adachi, et al. 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomised clinical trial J Clin Endocrinol Metab 87 3609 3617
28. OH Sorensen GM Crawford H Mulder, et al. 2003 Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 120 126
29. ST Harris NB Watts HK Genant, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1344 1352
30. J-Y Reginster HW Minne OH Sorensen, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 83 91
31. E Seeman 2002 Pathogenesis of bone fragility in women and men Lancet 359 1841 1850
32. JJ Stepan F Alenfeld G Boivin, et al. 2003 Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis Endocr Regul 37 225 238
33. H Hansdottir L Franzson K Prestwood G Sigurdsson 2004 The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities J Am Geriatr Soc 52 779 783
34. PJ Marie 2005 Strontium ranelate: a novel mode of action of optimizing bone formation and resorption Osteoporos Int 16 Suppl 1 S7 S10
35. R Baron Y Tsouderos 2002 In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation Eur J Pharmacol 450 11 17
36. N Chattopadhyay SJ Quinn O Kifor 2007 The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation Biochem Pharmacol 74 438 447
37. EM Brown M Pollak SC Hebert 1998 The extracellular calcium-sensing receptor: its role in health and disease Annu Rev Med 49 15 29
38. G Boivin D Farlay C Simi PJ Meunier 2006 Bone strontium distribution and degree of mineralisation of bone in postmenopausal women treated with strontium ranelate for 2 or 3 years Osteoporos Int 17 S86
39. G Boivin PJ Meunier 2006 Bone strontium content reaches a plateau after 3 years of treatment with strontium ranelate 2 g per day Arthritis Rheum 9 Suppl S59040
40. O Bruyere C Roux J Detilleux, et al. 2007 Relationship between bone mineral density changes ans fracture risk reduction in patients treated with strontium ranelate J Clin Endocrinol Metab 92 8 3076 3081
41. O Bruyere C Roux J Badurski, et al. 2007 Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranealte Cur Med Res Op 23 12 3041 45
42. P Marquis C Roux C de la Loge, et al. 2007 Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis Osteoporos Int 19 503 510
43. N Dursun E Dursun S Yalcin 2001 Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis Int J Clin Pract 55 505 509
44. SL Silverman ME Minshall W Shen, et al. 2001 The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study Arthritis Rheum 44 2611 2619
45. MC Nevitt P Chen RK Dore, et al. 2006 Reduced risk of back pain following teriparatide treatment: a meta-analysis Osteoporos Int 17 273 280